Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adverse events (AEs), and clinica...

Descripción completa

Detalles Bibliográficos
Autores: Marty, F. M., Man, C. Y., Van der Horst, C., Francois, B., Garot, D., Mánez, R., Thamlikitkul, V., Lorente Balanza, José Ángel, Álvarez Lerma, Francisco, Brealey, D., Zhao, H. H., Weller, S., Yates, P. J., Peppercorn, A. F.
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Universidad Europea (UEM)
Repositorio:ABACUS. Repositorio de Producción Científica
Idioma:español
OAI Identifier:oai:abacus.universidadeuropea.com:11268/4210
Acceso en línea:http://hdl.handle.net/11268/4210
Access Level:acceso abierto
Palabra clave:Zanamivir
Medicamentos
Investigación médica
Descripción
Sumario:Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adverse events (AEs), and clinical/laboratory parameters. Pharmacokinetics, viral load, and disease course were also assessed.

Similares en LA Referencia